Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous

A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous

Resource Type

CF Research News

Authors

Edward F McKone, Emily A DiMango, Sivagurunathan Sutharsan, Tara Lynn Barto, Daniel Campbell, Neil Ahluwalia, Mark Higgins, Caroline A Owen, Elizabeth Tullis

References

J Cyst Fibros. 2020 Dec 15;S1569-1993(20)30906-1. doi: 10.1016/j.jcf.2020.11.003.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

CFTR gating mutation [3]
Clinical trial [4]
F508del-CFTR mutation [5]
Ivacaftor [6]
Tezacaftor [7]

Date

Tuesday, December 15, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/phase-3-randomized-double-blind-parallel-group-study-evaluate

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00430R1_FINAL_McKone_171220%20%28002%29.pdf [2] https://pubmed.ncbi.nlm.nih.gov/33339768/ [3] https://www.ecfs.eu/research-article-keywords/cftr-gating-mutation [4] https://www.ecfs.eu/research-article-keywords/clinical-trial [5] https://www.ecfs.eu/research-article-keywords/f508del-cftr-mutation [6] https://www.ecfs.eu/research-article-keywords/ivacaftor [7] https://www.ecfs.eu/research-article-keywords/tezacaftor [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines